{"version":"1.0","type":"rich","provider_name":"Acast","provider_url":"https://acast.com","height":250,"width":700,"html":"<iframe src=\"https://embed.acast.com/$/634549cdd950350012c90fc5/6478ab5da0b2e30011f3de03?\" frameBorder=\"0\" width=\"700\" height=\"250\"></iframe>","title":"How might deucravacitinib fit into the treatment pathway for patients with SLE?","description":"<p>During the Lupus Hub Steering Committee meeting, key opinion leaders discussed how deucravacitinib might fit into the treatment pathway for patients with systemic lupus erythematosus (SLE). This recorded discussion was led by committee chair Ricard Cervera, and featured Murray Urowitz, Mandana Nikpour, Betty Diamond, James Cheng-Chung Wei, Manuel Francisco Ugarte-Gil, and Lyndsy Ambler.</p><p><br></p><p>In this podcast, the committee members discuss how deucravacitinib, a TYK2 inhibitor, might fit into the current treatment algorithm for patients with SLE, using a case study as the basis for their discussions. The recently published phase II trial data of deucravacitinib for the management of SLE is discussed, alongside the potential for the introduction of new drugs to influence treatment strategies. The committee members also look at the pathogenesis of lupus and consider how combination treatments may impact symptom reduction and earlier cessation.</p>","author_name":"Scientific Education Support"}